Viridian Therapeutics (VRDN) News Today

Company: Viridian Therapeutics, Inc. (NASDAQ:VRDN)

VRDN shares have been driven by a flurry of analyst moves ahead of its upcoming Q2 earnings release. While several firms have raised price targets on optimism around growth prospects and partnerships, others have trimmed forecasts, reflecting mixed sentiment on near-term valuation and profitability.

• Positive Sentiment: Goldman Sachs raised its price target on VRDN from $27.00 to $30.00 and maintained a “buy” rating, signaling confidence in the company’s growth prospects. The Goldman Sachs Group Issues Positive Forecast for Viridian Therapeutics Stock Price
• Positive Sentiment: Oppenheimer boosted its VRDN price objective from $28.00 to $32.00 and reiterated an “outperform” rating, pointing to improved outlook in late-stage development. Oppenheimer Increases Viridian Therapeutics Price Target to $32.00
• Positive Sentiment: Viridian entered a partnership with Kissei Pharmaceutical to develop thyroid eye disease therapies in Japan, expanding its international collaboration footprint. Viridian partners with Kissei Pharmaceutical
• Neutral Sentiment: Royal Bank of Canada lowered its price target on VRDN from $45.00 to $41.00 but maintained an “outperform” rating, reflecting cautious valuation trimming. Viridian Therapeutics Price Target Lowered to $41.00 at Royal Bank Of Canada
• Neutral Sentiment: Needham & Company trimmed its VRDN target from $36.00 to $34.00 while retaining a “buy” stance, indicating slight near-term caution. Needham & Company LLC Cuts VRDN Price Target to $34.00
• Neutral Sentiment: Wells Fargo reduced its VRDN objective from $27.00 to $26.00 and assigned an “equal weight” rating, pointing to a more balanced risk/reward view. VRDN Price Target Lowered to $26.00 at Wells Fargo & Company
• Neutral Sentiment: Analysts revised their forecasts following Viridian’s Q2 results, featuring mixed adjustments across ratings and price targets. Analysts Revise Forecasts on Viridian Following Q2 Results
• Neutral Sentiment: Viridian will report its Q2 2025 earnings on August 14 before market open, a key catalyst for stock volatility. VRDN to Release Earnings
• Negative Sentiment: Wedbush cut its FY2028 EPS forecast for VRDN from $5.43 to $5.11, signaling lower long-term profitability expectations. Wedbush Cuts FY2028 EPS Estimates